Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells.

abstract：:Knowledge about long-term consequences of breast cancer treatment on shoulder and arm function and volume in stages I-II breast cancer survivors is limited. The effects of shoulder-arm function shortly after surgery on long-term function are unknown. One hundred and ninety-four women were examined pre-surgery (T0) and...

journal_title：Breast cancer research and treatment

authors： Kootstra JJ,Dijkstra PU,Rietman H,de Vries J,Baas P,Geertzen JH,Hoekstra HJ,Hoekstra-Weebers JE

更新日期：2013-05-01 00:00:00

abstract：:Treatment decisions in oncology are based on a balance between the efficacy of therapy and its side effects. Patients with metastases and patients with a limited prognosis are a particular challenge, since communication about the disease situation and the expected therapeutic benefit is difficult not only for patients...

journal_title：Breast cancer research and treatment

authors： Lux MP,Bayer CM,Loehberg CR,Fasching PA,Schrauder MG,Bani MR,Häberle L,Engel A,Heusinger K,Tänzer T,Radosavac D,Scharl A,Bauerfeind I,Gesslein J,Schulte H,Overbeck-Schulte B,Beckmann MW,Hein A

更新日期：2013-06-01 00:00:00

abstract：:We have measured the levels of tamoxifen and three of its metabolites in the blood of patients receiving tamoxifen alone or combination therapy with tamoxifen and medroxyprogesterone acetate. Our results indicate that addition of the progestogen significantly alters the metabolism of tamoxifen over a six-month period....

journal_title：Breast cancer research and treatment

authors： Reid AD,Horobin JM,Newman EL,Preece PE

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:Complementary and alternative medicines (CAMS) are frequently used by patients with breast cancer and their use may be related to the presence of psychosocial distress. The objective of this study is to assess the presence of anxiety and depression in breast cancer patients who use CAM and assess how they perce...

journal_title：Breast cancer research and treatment

authors： Rakovitch E,Pignol JP,Chartier C,Ezer M,Verma S,Dranitsaris G,Clemons M

更新日期：2005-03-01 00:00:00

abstract：PURPOSE:To compare the prognostic significance of proliferation, as assessed by Ki67 expression, in breast cancer before and after neoadjuvant chemotherapy. METHODS:A retrospective search of a prospectively maintained clinical database was performed to identify patients treated with neoadjuvant chemotherapy at the Roy...

journal_title：Breast cancer research and treatment

authors： Jones RL,Salter J,A'Hern R,Nerurkar A,Parton M,Reis-Filho JS,Smith IE,Dowsett M

更新日期：2009-07-01 00:00:00

abstract：:Transforming growth factor-beta (TGFB) is a potent inhibitor of normal epithelial cell proliferation, and may be one of the regulatory factors that are perturbed during tumor development. While many tumor cell lines no longer respond to the inhibitory effects of TGFB due to a reduction or absence of the type II recept...

journal_title：Breast cancer research and treatment

authors： Barlow J,Yandell D,Weaver D,Casey T,Plaut K

更新日期：2003-05-01 00:00:00

abstract：BACKGROUND:We have constructed anti-HER2 immunoliposomes containing magnetite nanoparticles (HML) that generate heat in an alternating magnetic field (AMF). The effective targeting and cytocidal abilities of HML have been achieved using cell culture models. This study aimed to investigate feasibility of this modality f...

journal_title：Breast cancer research and treatment

authors： Kikumori T,Kobayashi T,Sawaki M,Imai T

更新日期：2009-02-01 00:00:00

abstract：:Breast cancer is the most common cancer among women. It is estimated that 7% of women who have breast cancer will develop a subsequent second independent breast tumor within 10 years of the first. The status of estrogen (ER), progesterone (PR) and human growth hormone (HER2) receptors, individually and as phenotypic c...

journal_title：Breast cancer research and treatment

authors： Brown M,Bauer K,Pare M

更新日期：2010-02-01 00:00:00

abstract：PURPOSE:HER2 gene is a member of the epidermal growth factor receptor (EGFR) family. Across different malignancies, aberrations of HER2 gene commonly correspond to gain-of-function alterations leading to increased receptor signaling. METHODS:We have reviewed the literature currently available on HER2 mutations in huma...

journal_title：Breast cancer research and treatment

authors： Petrelli F,Tomasello G,Barni S,Lonati V,Passalacqua R,Ghidini M

更新日期：2017-11-01 00:00:00

abstract：:EMSY is a putative oncogene amplified in a minority of breast carcinomas, its protein product interacts with and transcriptionally silences BRCA2. We hypothesized that breast tumors from BRCA2 mutation carriers would be less likely than other familial breast cancers to exhibit EMSY amplification. As EMSY is located on...

journal_title：Breast cancer research and treatment

authors： Bane AL,Mulligan AM,Pinnaduwage D,O'Malley FP,Andrulis IL

更新日期：2011-06-01 00:00:00

abstract：:A class distribution of plasma cells associated with the stroma in twenty-eight cases of medullary carcinoma of the breast was investigated by an unlabeled immunoperoxidase method. The stroma of the medullary carcinomas tested was found to contain predominantly IgG plasma cells except in two cases. Stroma of the other...

journal_title：Breast cancer research and treatment

authors： Ito T,Saga S,Nagayoshi S,Imai M,Aoyama A,Yokoi T,Hoshino M

更新日期：1986-01-01 00:00:00

abstract：BACKGROUND:Breast cancer is characterized by malignant transformation of epithelial cells, but stromal cells also play an important role in tumorigenesis. While tumor-derived fibroblasts display unique phenotypic properties, it is unclear whether they also represent are a specific subpopulation. MATERIALS AND METHODS:...

journal_title：Breast cancer research and treatment

authors： Singer CF,Gschwantler-Kaulich D,Fink-Retter A,Haas C,Hudelist G,Czerwenka K,Kubista E

更新日期：2008-07-01 00:00:00

abstract：:This review will focus on the role of sphingosine and its phosphorylated derivative sphingosine-1-phosphate (SPP) in cell growth regulation and signal transduction. We will show that many of the effects attributed to sphingosine in quiescent Swiss 3T3 fibroblasts are mediated via its conversion to SPP. We propose that...

journal_title：Breast cancer research and treatment

authors： Spiegel S,Olivera A,Zhang H,Thompson EW,Su Y,Berger A

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:To investigate the activity of the combination of gemcitabine (G) plus epirubicin (E) and taxol (T), (GET), in metastatic breast cancer, to evaluate the feasibility of this regimen as induction before high dose chemotherapy and to study the pharmacokinetic interactions of these three drugs. PATIENTS AND METHOD...

journal_title：Breast cancer research and treatment

authors： Conte PF,Gennari A,Donati S,Salvadori B,Baldini E,Bengala C,Pazzagli I,Orlandini C,Danesi R,Fogli S,Del Tacca M

更新日期：2001-07-01 00:00:00

abstract：PURPOSE:Discordance between HER2 expression in tumor tissue (tHER2) and HER2 status on circulating tumor cells (cHER2) has been reported. It remains largely underexplored whether patients with tHER2-/cHER2+ can benefit from anti-HER2 targeted therapies. METHODS:cHER2 status was determined in 105 advanced-stage patient...

journal_title：Breast cancer research and treatment

authors： Wang C,Mu Z,Ye Z,Zhang Z,Abu-Khalaf MM,Silver DP,Palazzo JP,Jagannathan G,Fellin FM,Bhattacharya S,Jaslow RJ,Tsangaris TN,Berger A,Neupane M,Cescon TP,Lopez A,Yao K,Chong W,Lu B,Myers RE,Hou L,Wei Q,Li B,Cri

更新日期：2020-06-01 00:00:00

abstract：:Feasibility of utilizing the 6-day subrenal capsule (SRC) assay to screen drugs against fresh surgical explants of human tumors was confirmed by testing six clinically active chemotherapeutic agents against 141 human breast cancers. Response rates of the six drugs obtained in the assay compared favorably with clinical...

journal_title：Breast cancer research and treatment

authors： Bogden AE,Costanza ME,Reich SD,Griffin TW,Cobb WR

更新日期：1983-01-01 00:00:00

abstract：:One in six primary human breast cancers has DNA amplification centered on the cyclin D1 gene (CCND1) on chromosome 11q13. This genetic abnormality is preferentially associated with estrogen-receptor positive tumors and may define a sub-class of patients with an adverse prognosis. Although CCND1 has the credentials of ...

journal_title：Breast cancer research and treatment

authors： Peters G,Fantl V,Smith R,Brookes S,Dickson C

更新日期：1995-01-01 00:00:00

abstract：:The prognostic value of epidermal growth factor receptor (EGF-R) was prospectively assessed in a series of 229 clinical T1-T2, N0-N1 breast carcinomas diagnosed between May 1987 and October 1989. EGF-R expression was determined by measuring the specific Bmax of 125I EGF to tumor plasma membrane preparations. Tumor wit...

journal_title：Breast cancer research and treatment

authors： Bolla M,Chedin M,Colonna M,Marron-Charrière J,Rostaing-Puissant B,Pasquier D,Panh MH,Winckel P,Chambaz EM

更新日期：1994-01-01 00:00:00

abstract：:IBEP-2, an established cell line recently derived from breast carcinoma, was characterized with regard to estrogen receptor (ER) expression, cell mitogenic response to estrogenic stimulation and sensitivity to antiestrogens. In addition, we examined ER modulation following binding of agonist and antagonists, and the E...

journal_title：Breast cancer research and treatment

authors： Journé F,Body JJ,Leclercq G,Nonclercq D,Laurent G

更新日期：2004-07-01 00:00:00

abstract：PURPOSE:RAD51C is known as an ovarian cancer gene; however, its role in breast cancer susceptibility is less clear. As part of a larger study, we assessed the role of germline RAD51C mutations in breast cancer development. METHODS:We studied 387 unselected, BRCA1- and BRCA2-negative, Bahamian breast cancer cases and 6...

journal_title：Breast cancer research and treatment

authors： Bagherzadeh M,Szymiczek A,Donenberg T,Butler R,Hurley J,Narod SA,Akbari MR

更新日期：2020-11-01 00:00:00

abstract：PURPOSE:To evaluate the efficacy and safety of erlotinib in advanced breast cancer. Experimental design Multicenter, phase II study of erlotinib (150 mg orally daily). Cohort 1: progression after anthracyclines, taxanes, and capecitabine (n = 47). Cohort 2: progression after >1 chemotherapy for advanced-stage disease (...

journal_title：Breast cancer research and treatment

authors： Dickler MN,Cobleigh MA,Miller KD,Klein PM,Winer EP

更新日期：2009-05-01 00:00:00

abstract：:There are increasing evidences that HSD17B1 plays a significant role in the development of breast cancer. However, published data on the association between HSD17B1 Ser312Gly polymorphism and breast cancer risk are inconclusive. In order to derive a more precise estimation of this relationship, a meta-analysis includi...

journal_title：Breast cancer research and treatment

authors： Yao L,Cao LH,Qiu LX,Yu L

更新日期：2010-09-01 00:00:00

abstract：:Few studies have assessed the agreement between subjects' self-report and medical records among patients with breast cancer (BC), and none has addressed this issue in low-income women with BC. We assessed the level of agreement between self-report and medical records data for key BC treatment and prognostic characteri...

journal_title：Breast cancer research and treatment

authors： Liu Y,Diamant AL,Thind A,Maly RC

更新日期：2010-02-01 00:00:00

abstract：:A major goal of cancer chemotherapy is the identification of cytotoxic compounds that are highly selective for cancer cells. We describe here one such compound - a novel iron chelator, desferri-exochelin 772SM. This desferri-exochelin has unique chemical and pharmacological properties, including extremely high iron bi...

journal_title：Breast cancer research and treatment

authors： Pahl PM,Horwitz MA,Horwitz KB,Horwitz LD

更新日期：2001-09-01 00:00:00

abstract：BACKGROUND:The genes mutated in the cancer-prone syndrome, xeroderma pigmentosum (XP genes), have been well studied both biochemically and mechanistically. These genes are important components of the DNA nucleotide excision repair (NER) pathway, which protects against environmentally-induced cancers. XP genes are also ...

journal_title：Breast cancer research and treatment

authors： Jorgensen TJ,Visvanathan K,Ruczinski I,Thuita L,Hoffman S,Helzlsouer KJ

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:The anatomy of the nipple has become clinically relevant. Diagnostic techniques access the breast through nipple ducts and surgeons offer nipple-sparing mastectomy. There is variation in the number of ducts reported and little is known about the spatial location of ducts, their size, and their relationship t...

journal_title：Breast cancer research and treatment

authors： Rusby JE,Brachtel EF,Michaelson JS,Koerner FC,Smith BL

更新日期：2007-12-01 00:00:00

abstract：:The purpose of this article is to comprehensively summarize the associations between carotenoids and breast cancer and quantitatively estimate their dose-response relationships. We searched PubMed, Embase, and Cochrane databases (from January 1982 to 1 May 2011) and the references of the relevant articles in English w...

journal_title：Breast cancer research and treatment

authors： Hu F,Wang Yi B,Zhang W,Liang J,Lin C,Li D,Wang F,Pang D,Zhao Y

更新日期：2012-01-01 00:00:00

abstract：PURPOSE:In rodents, a single exercise bout performed 24 h prior to a single doxorubicin treatment provides cardio-protection. This study investigated whether performing this intervention prior to every doxorubicin treatment for breast cancer reduced subclinical cardiotoxicity and treatment symptoms. METHODS:Twenty-fou...

journal_title：Breast cancer research and treatment

authors： Kirkham AA,Eves ND,Shave RE,Bland KA,Bovard J,Gelmon KA,Virani SA,McKenzie DC,Stöhr EJ,Waburton DER,Campbell KL

更新日期：2018-02-01 00:00:00

abstract：PURPOSE:Based on available phase III trial data, we performed a cost-effectiveness analysis of different treatment strategies that can be used in patients with newly diagnosed HER2-positive metastatic breast cancer (mBC). PATIENTS AND METHODS:We constructed a Markov model to assess the cost-effectiveness of four diffe...

journal_title：Breast cancer research and treatment

authors： Diaby V,Adunlin G,Ali AA,Zeichner SB,de Lima Lopes G,Kohn CG,Montero AJ

更新日期：2016-11-01 00:00:00

abstract：:Tamoxifen citrate is a synthetic antiestrogen that provides survival benefit when given as adjuvant treatment in postmenopausal women with breast cancer. Venous thrombophlebitis may complicate tamoxifen treatment at a rate of approximately one per 800 treatment-years. To explore the possible procoagulant effects assoc...

journal_title：Breast cancer research and treatment

authors： Mamby CC,Love RR,Feyzi JM

更新日期：1994-01-01 00:00:00